FDA Authorizes Novavax's Updated COVID-19 Vaccine for JN.1 Strain, Age 12 and Older

Aug 30, 2024, 06:51 PM

The U.S. Food and Drug Administration (FDA) has authorized an updated version of the Novavax COVID-19 vaccine for emergency use. This updated 2024-2025 Formula vaccine targets the currently circulating variants, specifically the JN.1 strain, and is intended to provide better protection against serious consequences of COVID-19, including hospitalization and death. It is authorized for individuals aged 12 and older. The approval comes a week after the FDA authorized updated mRNA vaccines from Moderna and Pfizer for the KP.2 variant. The Novavax vaccine offers a protein-based immunization option and is expected to be available in pre-filled syringes across the U.S. in the coming days.